Leading the Way in Innovative Research for COVID-19 Patients

curncman
Posts: 905
Joined: Fri Jun 26, 2020 8:27 am

Leading the Way in Innovative Research for COVID-19 Patients

Post by curncman »

Leading the Way in Innovative Research for COVID-19 Patients

As the COVID-19 pandemic continues, there is great interest in studying treatment and prevention approaches for the disease. Cleveland Clinic is participating in a number of research projects related to COVID-19. As an international leader in biomedical research, Cleveland Clinic has formed a multidisciplinary clinical trials committee to evaluate therapies for mild to severe disease, with the goal of supporting trials that are scientifically sound and prioritizing those with the potential for significant impact on clinical care.

Among others, some of the clinical trials conducted at Cleveland Clinic include:

Therapeutic Studies
COVIDAtoZ
This investigator-initiated trial looks at the effect of high dose vitamin C and zinc in outpatient COVID-19 patients on symptom severity and duration and hospitalization. This is a single-center, prospective, randomized study. Some patients will receive high dose vitamin C, some high dose zinc, some both, and some will receive neither.
Learn more about this clinical trial.

Mesenchymal Stromal Cells in COVID-19 ARDS (Acute Respiratory Distress Syndrome)
The mortality rate in COVID-19 related severe ARDS is high despite treatment with antivirals, glucocorticoids, immunoglobulins, and ventilation. Preclinical and clinical evidence indicate that MSCs migrate to the lung counteract the inflammatory process by reducing the production pro-inflammatory cytokines (small proteins), increasing the production of anti-inflammatory cytokines enabling recruitment of naturally occurring anti-inflammatory cells to involved tissue. Therefore, MSCs may have the potential to increase survival in management of COVID-19 induced ARDS.
The primary objective of this multi-center, phase 3 trial is to evaluate the efficacy and safety of the addition of the mesenchymal stromal cell (MSC) remestemcel-L plus standard of care compared to placebo plus standard of care in patients with acute respiratory distress syndrome (ARDS) due to SARS-CoV-2. The secondary objective is to assess the impact of MSCs on inflammatory biomarkers. The study is through the Cardiothoracic Surgical Trials Network and sponsored through the NHLBI.
Learn more about this clinical trial.

Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection (ALI)
The study aims to assess the potential benefit and evaluate the safety and tolerability of a single subcutaneous dose of VIB7734 in hospitalized patients with documented COVID-19 infection with pulmonary involvement. Participants will be followed for 30 days to assess the effectiveness of the treatment and monitored for 10 weeks for safety. The aim of the drug is to regulate the immune response associated with COVID-19 infection as it is a monoclonal antibody that depletes peripheral dendritic cells, which are involved in inflammation.
Learn more about this clinical trial.

ILIAD-7:Interleukin 7 to Improve Outcomes in Lymphopenic Patients w/ COVID-19
This study is designed to evaluate the potential ability of IL-7 (CYT107) to decrease Intensive Care Unit (ICU) treatment requirements and reduce mortality by reversing lymphopenia (a lower-than-normal number of lymphocytes (a type of white blood cell) in the blood). and T cell exhaustion in COVID-19 patients, or accelerating such reversal, and avoiding, reducing or resolving secondary infections. Although multiple studies are aimed at treatments for the inflammatory characteristics of COVID-19 infection, lymphopenia and T-cell exhaustion have been largely overlooked as a focus for treatment intervention and to date, are major factors in COVID-19 mortality.
Learn more about this clinical trial.

Other research
COVID-19 Research Registry
A research registry of nearly 23, 000 patients is collecting data from patients tested for COVID-19 at Cleveland Clinic. This research registry, which includes patients with positive and negative results, will be able inform other studies, such as the development of tools to predict risk and outcomes in patients. Researchers from across the Cleveland Clinic enterprise are using the dynamic registry data in more than 140 COVID-19 related research projects in areas such as cancer, pediatrics, intensive care.

Convalescent Plasma
Cleveland Clinic and Cleveland Clinic Florida has an expanded access protocol for the use of convalescent plasma therapy for patients admitted with moderate to severe COVID-19. Convalescent plasma therapy, which collects antibody rich plasma from donors who have recovered from COVID-19, is used for patients currently struggling with the virus. In Florida, the convalescent plasma collection will be collected by OneBlood, an independent not-for-profit blood bank serving Florida. In Ohio, the American Red Cross and other blood centers are collecting and distributing convalescent plasma and are seeking potential donors.

AI Drug Repurposing for COVID-19
Cleveland Clinic researchers published findings last month on a network-based prediction model using artificial intelligence to identify targets for drug repurposing in coronavirus and COVID-19. Their approach targets the interaction between human and virus proteins rather than the virus protein itself. Based on their findings, they prioritized 16 drugs and three drug combinations as potential treatments.

American Heart Association COVID-19 Heart and Brain Research Initiative
The American Heart Association has awarded $1.2 million in grants to teams at 12 institutions across the U.S. to begin fast-tracked studies of the effects of COVID-19 on the body’s cardiovascular and cerebrovascular systems. Cleveland Clinic will serve as the initiative’s COVID-19 Coordinating Center and will collect results from the research projects and coordinate the dissemination of all study findings.
Learn more about this initiative.

Tracking COVID-19 Transmission Patterns
A team of Cleveland Clinic and Case Western Reserve University researchers is analyzing COVID-19 patient data to better understand how the virus spreads and where various strains originate. Supported by a special COVID-19 fund from the National Science Foundation (NSF), the team is conducting an epidemiologic analysis using data from patient samples collected at Cleveland Clinic. They will sequence the genome from about 400 of the 2,000 samples to study mutations and use computational algorithms to mine patterns from the genetic sequences. Coupled with epidemiologic data from each affected individual, such as demographic information and diagnosis date, the information will provide new insights into transmission patterns of the novel coronavirus, SARS-CoV-2.

Identifying Ways to Improve Experience and Quality of Care among Patients with COVID-19 Managed at Home
In this study, researchers will use a mixed methods approach to assess the experience and quality of care of Cleveland Clinic patients with COVID-19 being managed at home. Many Cleveland Clinic patients with COVID-19 are being managed at home using the MyChart Care Companion tool, which provides virtual check-ins and digital care management to facilitate cross-continuum engagement, remote monitoring and patient reported outcomes (PROMs) data collection. All Cleveland Clinic patients with COVID-19 are eligible for the study, regardless of whether or not they enroll in Care Companion. The study will assess whether or not Care Companion is associated with improved patient experience, reduced anxiety at home, improved self-care management, higher knowledge of COVID-19, improved outcomes and higher quality care.

National Cancer Institute’s Serological Sciences Network for COVID-19
A collaboration between Cleveland Clinic and Case Western Reserve University is part of the National Cancer Institute’s Serological Sciences Network for COVID-19 (SeroNet). A newly launched initiative, SeroNet comprises some of the nation’s top biomedical research centers, bringing immunology experts together to better understand the immune system’s response to COVID-19. The network aims to combat the pandemic by improving the ability to test for infection and speed the development of treatments and vaccines.
Howzitgoing
Posts: 48
Joined: Mon Jul 13, 2020 8:37 am

Re: Leading the Way in Innovative Research for COVID-19 Patients

Post by Howzitgoing »

Nasal Spray Prevents Covid Infection in Ferrets, Study Finds
> Scientists have developed a treatment that blocks the virus in the nose and lungs of lab animals. It’s inexpensive and needs no refrigeration.

Yea to ferrets. Keyword: BLOCKS.

Ferrets are used by scientists studying flu, SARS and other respiratory diseases because the animals can catch viruses through the nose much like humans do.
Ferret.jpg
Ferret.jpg (82.73 KiB) Viewed 1028 times

The spray attacks the virus directly. It contains a lipopeptide, a cholesterol particle linked to a chain of amino acids, the building blocks of proteins. This particular lipopeptide exactly matches a stretch of amino acids in the spike protein of the virus, which the pathogen uses to attach to a human airway or lung cell.

Before a virus can inject its RNA into a cell, the spike must effectively unzip, exposing two chains of amino acids, in order to fuse to the cell wall. As the spike zips back up to complete the process, the lipopeptide in the spray inserts itself, latching on to one of the spike’s amino acid chains and preventing the virus from attaching.

“It is like you are zipping a zipper but you put another zipper inside, so the two sides cannot meet,” said Matteo Porotto, a microbiologist at Columbia University and one of the paper’s authors.

After 24 hours together, none of the sprayed ferrets caught the disease; all the placebo-group ferrets did.

“Virus replication was completely blocked,” the authors wrote.

https://www.nytimes.com/2020/11/05/heal ... spray.html
Nasal Spray Prevents Covid Infection in Ferrets, Study Finds
Howzitgoing
Posts: 48
Joined: Mon Jul 13, 2020 8:37 am

Re: Leading the Way in Innovative Research for COVID-19 Patients

Post by Howzitgoing »

'Breakthrough finding' reveals why certain Covid-19 patients die

What makes some patients so much sicker than others?

Why does one 40-year-old get really sick and another one not even need to be admitted?

In some cases, provocative new research shows, some people — men in particular — succumb because their immune systems are hit by friendly fire.

In an international study in Science, 10 percent of nearly 1,000 Covid-19 patients who developed life-threatening pneumonia had antibodies that disable key immune system proteins called interferons. These antibodies — known as autoantibodies, because they attack the body itself — weren't found at all in 663 people with mild or asymptomatic Covid-19 infections. Only four of 1,227 healthy patients had the autoantibodies. The study was led by the Covid Human Genetic Effort, which includes 200 research centers in 40 countries.

https://www.yahoo.com/news/why-covid-19 ... 11975.html
'Breakthrough finding' reveals why certain Covid-19 patients die

https://science.sciencemag.org/content/ ... 5/eabd4570
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
> The immune system is complex and involves many genes, including those that encode cytokines known as interferons (IFNs). Individuals that lack specific IFNs can be more susceptible to infectious diseases. Furthermore, the autoantibody system dampens IFN response to prevent damage from pathogen-induced inflammation.

https://www.covidhge.com/
COVID Human Genetic Effort
Howzitgoing
Posts: 48
Joined: Mon Jul 13, 2020 8:37 am

Re: Leading the Way in Innovative Research for COVID-19 Patients

Post by Howzitgoing »

Anti-depressant for Covid-19 beginning stages ... Clinical trial by MAIL

Researchers at Washington University of St. Louis are recruiting 1,100 people in the beginning stages of Covid-19 to test out the drug fluvoxamine, also known as Luvox.

While an anti-depressant may seem like an unlikely candidate to fight Covid-19, a small study in November indicated it might have some success, and it's been known for years that modern anti-depressants, called selective serotonin reuptake inhibitors, have anti-inflammatory properties. Inflammation plays a key role in Covid-19, resulting in complications such as blood clots and swollen "Covid toes."

In order to get results in weeks instead of months -- an important time difference while thousands are dying of Covid-19 every day - researchers are conducting the study in an unorthodox way. They're mailing the medicine to patients' homes around the country, and patients will monitor their health and report back to study staff, instead of having patients go to the researchers.

The Washington University researchers are looking for participants who have tested positive for Covid-19 and have had symptoms for a week or less.

[More]

https://www.cnn.com/2021/01/11/health/f ... ent-study/
Doctors test popular anti-depressant to see if it fights off Covid-19

https://en.wikipedia.org/wiki/Fluvoxamine
Fluvoxamine
Howzitgoing
Posts: 48
Joined: Mon Jul 13, 2020 8:37 am

Re: Leading the Way in Innovative Research for COVID-19 Patients

Post by Howzitgoing »

Plant-based antiviral drug may help beat COVID-19, research shows

An antiviral medication derived from Thaspia may be "highly effective" in treating the coronavirus.
Thaspia.png
Thaspia.png (216.98 KiB) Viewed 768 times

A plant-derived antiviral medication may be “highly effective” in treating the coronavirus — and could also help fight future pandemics, according to new research in the UK.

Researchers at the University of Nottingham found that the broad spectrum antiviral thapsigargin is not only very effective against COVID-19, but also against a common cold coronavirus called respiratory syncytial virus and the influenza A, Eurekalert.org reported.

“Whilst we are still at the early stages of research into this antiviral and its impact on how viruses such as COVID-19 can be treated, these findings are hugely significant,” said Professor Kin-Chow Chang, who led the study along with colleagues at the Animal and Plant Health Agency, China Agricultural University and the Pirbright Institute.

“The current pandemic highlights the need for effective antivirals to treat active infections, as well as vaccines, to prevent the infection,” he said.

“Given that future pandemics are likely to be of animal origin, where animal to human and reverse zoonotic (human to animal) spread take place, a new generation of antivirals, such as thapsigargin, could play a key role in the control and treatment of important viral infections in both humans and animals,” Chang added.

The scientists found that the antiviral, at small doses, triggers a “highly effective” immune response against the three major types of human respiratory viruses, including COVID-19.

Thapsigargin, which has been tested in prostate cancer, is effective against viral infection when used before or during active infection, according to the study.

It is able to prevent a virus from making new copies of itself in cells for at least 48 hours after a single 30-minute exposure, according to the study.

“Although more testing is clearly needed, current findings strongly indicate that thapsigargin and its derivatives are promising antiviral treatments against COVID-19 and influenza virus, and have the potential to defend us against the next Disease X pandemic,” Chang said.

https://www.eurekalert.org/pub_releases ... 020121.php
Scientists uncover potential antiviral treatment for COVID-19
University of Nottingham

The key features based on cell and animal studies, which make thapsigargin a promising antiviral are that it is:

effective against viral infection when used before or during active infection

able to prevent a virus from making new copies of itself in cells for at least 48 hours after a single 30-minute exposure.

stable in acidic pH, as found in the stomach, and therefore can be taken orally, so could be administered without the need for injections or hospital admission.

not sensitive to virus resistance.

at least several hundred-fold more effective than current antiviral options.

just as effective in blocking combined infection with coronavirus and influenza A virus as in single-virus infection.

safe as an antiviral (a derivative of thapsigargin has been tested in prostate cancer).
Howzitgoing
Posts: 48
Joined: Mon Jul 13, 2020 8:37 am

Re: Leading the Way in Innovative Research for COVID-19 Patients

Post by Howzitgoing »

Neanderthal gene found to sharply reduce COVID-19 risk

Neanderthal gene.png
Neanderthal gene.png (398.81 KiB) Viewed 529 times

ONNA, Okinawa Prefecture--New research suggests a gene that reduces the risk of developing serious COVID-19 symptoms is inherited from Neanderthals, a species of human that died out 40,000 years ago.

Researchers headed by Svante Paabo, a human evolutionary genomics professor at the Okinawa Institute of Science and Technology Graduate University here, found that 30 percent of Japanese as well as roughly half the population of the Eurasian land mass today have the characteristic.

“People marked by the specific genetic type appear to be able to more efficiently destroy viruses invading cells, such as the novel coronavirus,” said Paabo, adding that the genetic feature is believed to reduce the risk of COVID-19 progression by about 20 percent.

Paabo and his team members studied a gene known as OAS on the 12th chromosome in all 46 chromosomes, or 23 pairs, found in each human cell. The gene is associated with the production of a particular enzyme.

It is one of the genes that are suspected to be linked to COVID-19 symptoms by a different research team based on its analysis of 2,000 novel coronavirus patients in a serious condition.

The genetic feature connected to the gene was identified in Neanderthal remains uncovered in Croatia and southern Siberia, though ancient people in Africa, considered the cradle of mankind, did not have the factor.

As modern humans are thought to have crossbred with Neanderthals 60,000 years ago, Paabo's research suggests the trait was transmitted to people around that time.

The findings were published in the online edition of PNAS, the bulletin of the U.S. National Academy of Sciences, at (https://www.pnas.org/content/118/9/e2026309118).

Last year, Paabo’s team discovered a different genetic type that also derives from Neanderthals but works in the opposite way to that of the factor explained in the latest finding and triggers a higher risk of severe COVID-19 progression.

The risk factor for progression was found in areas of Europe and South Asia, but few patients in Japan and other parts of East Asia were found to have the characteristic.

For that reason, the genetic feature is presumed to at least partially explain the relative paucity of people with COVID-19 in East Asia developing severe conditions.

http://www.asahi.com/ajw/articles/14243394
Howzitgoing
Posts: 48
Joined: Mon Jul 13, 2020 8:37 am

Re: Leading the Way in Innovative Research for COVID-19 Patients

Post by Howzitgoing »

How mRNA Technology Could Change the World
>mRNA’s story likely will not end with COVID-19: Its potential stretches far beyond this pandemic.

Excerpts:
Synthetic mRNA, the ingenious technology behind the Pfizer-BioNTech and Moderna vaccines, might seem like a sudden breakthrough, or a new discovery. One year ago, almost nobody in the world knew what an mRNA vaccine was, for the good reason that no country in the world had ever approved one. Months later, the same technology powered the two fastest vaccine trials in the history of science.

People rely on proteins for just about every bodily function; mRNA—which stands for messenger ribonucleic acid—tells our cells which proteins to make. With human-edited mRNA, we could theoretically commandeer our cellular machinery to make just about any protein under the sun. You could mass-produce molecules that occur naturally in the body to repair organs or improve blood flow. Or you could request our cells to cook up an off-menu protein, which our immune system would learn to identify as an invader and destroy.

But mRNA’s story likely will not end with COVID-19: Its potential stretches far beyond this pandemic. This year, a team at Yale patented a similar RNA-based technology to vaccinate against malaria, perhaps the world’s most devastating disease. Because mRNA is so easy to edit, Pfizer says that it is planning to use it against seasonal flu, which mutates constantly and kills hundreds of thousands of people around the world every year. The company that partnered with Pfizer last year, BioNTech, is developing individualized therapies that would create on-demand proteins associated with specific tumors to teach the body to fight off advanced cancer. In mouse trials, synthetic-mRNA therapies have been shown to slow and reverse the effects of multiple sclerosis. “I’m fully convinced now even more than before that mRNA can be broadly transformational,” Özlem Türeci, BioNTech’s chief medical officer, told me. “In principle, everything you can do with protein can be substituted by mRNA.”

Merck, which had recently developed an astonishingly successful vaccine against Ebola using a modified livestock virus called vesicular stomatitis virus, or VSV. But Merck discontinued its COVID-19 vaccines when its promising new technology failed in clinical trials.

Hotez sees Merck’s failures as a critical lesson about science—and a cautionary tale about mRNA.“The technology that works for one epidemic might not work for the next one, and you won’t know what works until you try it,” he told me. “That’s why I say it’s too soon to call mRNA vaccines a miracle. They might not work against the next target.”

Even mRNA’s biggest proponents concede the point. “This is not a magic bullet, and it’s not perfect for everything,” Pfizer’s Dormitzer told me. His partners at BioNTech concurred. “I do not claim that mRNA is the holy grail for everything,” Türeci said. “We are going to find that there are diseases where mRNA is surprisingly successful and diseases where it’s not. We have to prove it for each and every infectious disease, one by one.”

https://www.theatlantic.com/ideas/archi ... ket-newtab
How mRNA Technology Could Change the World
curncman
Posts: 905
Joined: Fri Jun 26, 2020 8:27 am

Dr. Roger Seheult from MedCram on COVID-19 Vaccines, Vitamin D, and Heat Hydrotherapy

Post by curncman »

Dr. Roger Seheult from MedCram on COVID-19 Vaccines, Vitamin D, and Heat Hydrotherapy

curncman
Posts: 905
Joined: Fri Jun 26, 2020 8:27 am

Nasal COVID Vaccines - GAME CHANGERS

Post by curncman »

Nasal COVID Vaccines - GAME CHANGERS


curncman
Posts: 905
Joined: Fri Jun 26, 2020 8:27 am

A big review on immunity from COVID infections and/or vaccinations

Post by curncman »

A big review on immunity from COVID infections and/or vaccinations as documented by the recent NIAID and NIH study. Please reference my Facebook page post from 4/5/21 or our website blog to see the journal article summary direct from the NIH. Tough questions are discussed concerning whether to get the vaccine if you have been previously infected. Why should we resume normal activity if vaccinated or previously infected is highlighted? If you are an adult who hasn't been vaccinated or had the infection please consider getting inoculated to limit disease spread and help return the country to normalcy.

Noel Robert Williams MD

Post Reply